Solid Biosciences Inc.
General ticker "SLDB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $612.0M (TTM average)
Solid Biosciences Inc. follows the US Stock Market performance with the rate: 53.6%.
Estimated limits based on current volatility of 3.0%: low 9.61$, high 10.20$
Factors to consider:
- Total employees count: 121 (+21.0%) as of 2025
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Economic downturns and volatility, Geopolitical risks, Acquisition/divestiture risks
- Current price 16.7% above estimated high
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.03$, 8.82$]
- 2026-12-31 to 2027-12-31 estimated range: [2.50$, 7.52$]
Financial Metrics affecting the SLDB estimates:
- Positive: with PPE of -2.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -30.76 <= 0.28
- Negative: negative Net income
- Positive: -14.39 < Investing cash flow per share per price, % of -11.50
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 77.41 > 63.63
Short-term SLDB quotes
Long-term SLDB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $104.25MM | $129.73MM | $179.21MM |
| Operating Income | $-104.25MM | $-129.73MM | $-179.21MM |
| Non-Operating Income | $8.24MM | $5.03MM | $4.88MM |
| Interest Expense | $0.44MM | $0.34MM | $0.20MM |
| R&D Expense | $76.56MM | $96.43MM | $140.32MM |
| Income(Loss) | $-96.02MM | $-124.70MM | $-174.32MM |
| Net Income(Loss)* | $-96.02MM | $-124.70MM | $-174.32MM |
| Stockholders Equity | $126.48MM | $137.25MM | $180.01MM |
| Assets | $164.94MM | $188.66MM | $232.54MM |
| Operating Cash Flow | $-94.18MM | $-100.01MM | $-156.29MM |
| Capital expenditure | $1.51MM | $0.65MM | $1.15MM |
| Investing Cash Flow | $9.69MM | $-16.09MM | $-58.45MM |
| Financing Cash Flow | $3.12MM | $122.44MM | $194.45MM |
| Earnings Per Share** | $-4.83 | $-3.06 | $-1.99 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.